Kintara Therapeutics Inc Stock

$2.66

2.21% yesterday

Nasdaq, Jun 11, 10:00 pm CET

ISIN

US49720K1016

Symbol

HURA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Trade

Industry

Wholesale

Overview Dividends Analysts Charts News Strategies

Kintara Therapeutics Inc Stock price

$2.66

-861.23 99.69% 5Y

Nasdaq, Closing price Wed, Jun 11 2025

-0.06 2.21%

ISIN

US49720K1016

Symbol

HURA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Trade

Industry

Wholesale

Key metrics

Market capitalization	$116.19m
Enterprise Value	$109.97m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	11.79
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-27.05m
Free Cash Flow (TTM) Free Cash Flow	$-21.01m
Cash position	$6.22m
EPS (TTM) EPS	$-0.72
P/E forward	negative
Short interest	6.07%

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Get Started for Free Today

Kintara Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Kintara Therapeutics Inc forecast:

2x Buy

100%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Kintara Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Kintara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	9.03 9.03	89% 89% -
- Research and Development Expense	18 18	288% 288% -
EBITDA	-27 -27	187% 187% -
- Depreciation and Amortization	0.15 0.15	200% 200% -
EBIT (Operating Income) EBIT	-27 -27	187% 187% -
Net Profit	-32 -32	232% 232% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Kintara Therapeutics Inc Stock News

Neutral

PRNewsWire

●

3 days ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

NEW YORK , June 9, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: TuHURA Biosciences, Inc. (NASDAQ: HURA)'s merger with Kineta, Inc. If you are a TuHURA shareholder, click here to learn more about your legal right...

Neutral

PRNewsWire

●

3 days ago

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) Agreement with U.S. Food and Drug Administration (FDA), later in June 2025 Resolution of partial clinical hold unlocks second tran...

Neutral

PRNewsWire

●

9 days ago

TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy

Secures $12.5 million of commitments in a private offering Secures an additional $3.0 million through payment of cash exercise price of warrants Funding provides capital for: Initiation of planned Phase 3 accelerated approval trial of IFx-2.0 targeting 40% enrollment by 2-2025 year end Acquisition of and initiating a Phase 2 trial in NPM1 mutated AML, a novel VISTA inhibiting antibody through c...

More Kintara Therapeutics Inc News

Company Profile

Kintara Therapeutics, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. Its pipeline includes the VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.

Head office	United States
CEO	James Bianco
Founded	2009
Website	www.kintara.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now